Standard AI vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Computer vision analytics platform for retail deployed across 24 countries; pivoted from autonomous checkout to VISION Analytics (shelf availability, merchandising, loss prevention) in 2024; acquired Pathr.ai Jan 2026; ~$236M raised.
About
Standard AI is a San Francisco-based retail technology company founded in 2012 that applies computer vision and AI to give physical retailers real-time visibility into store operations. Originally launched as an autonomous checkout provider — deploying grab-and-go cashierless retail systems — the company underwent a significant strategic pivot in 2024 under a new CEO, exiting the autonomous checkout market and refocusing on its VISION Analytics platform. VISION provides retailers with actionable, privacy-compliant insights derived from existing camera infrastructure, covering shelf availability, planogram compliance, traffic flow analysis, merchandising impact prediction, and loss prevention.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.